Invitrogen

Human RWDD3 Synthetic Peptide

Product Details

PEP-0935

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species Reactivity

Human

Class

Synthetic

Type

Peptide

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

purified

Storage buffer

PBS, pH 7.2, with 0.1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C

Product Specific Information

This peptide corresponds to 17 amino acids near the amino terminus of human RWDD3.

PEP-0935 can be used as a blocking peptide with polyclonal antibody PA5-20821.

Target Information

RWDD3 (RSUME), a small RWD-containing protein, has a central role in sumoylation by enhancing SUMO conjugation in the regulatory network of immune-inflammatory signals. RWDD3 increases Ikappa-Beta sumoylation and stability. In addition, RWDD3 inhibits TNF-a-induced kappaB-LUC (Luciferase) reporter activity, showing the functional consequence of Ikappa-Beta increased stability. RSUME-enhanced sumoylation of Ikappa-Beta leads to the inhibition of NF-kappa-Beta activity on two well-known inflammatory genes, IL-8 and cyclooxygenase-2 (Cox-2) and therefore may also favor anti-inflammatory pathways. Expression of RWDD3 was induced under hypoxic conditions and it has a potential role during vascularization. Both BMP-4 and RWDD3 may be interesting targets for inhibiting steps involved in pituitary tumorigenesis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: RSUME; RWD domain-containing protein 3; RWD domain-containing sumoylation enhancer; RWD-containing sumoylation enhancer